Catalyst Pharmaceuticals (CPRX) – Research Analysts’ Weekly Ratings Changes

Posted by Latisha Jones on Mar 12th, 2025

Catalyst Pharmaceuticals (NASDAQ: CPRX) has recently received a number of price target changes and ratings updates:

3/3/2025 – Catalyst Pharmaceuticals had its price target raised by analysts at Robert W. Baird from $28.00 to $32.00. They now have an “outperform” rating on the stock.
2/28/2025 – Catalyst Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
2/28/2025 – Catalyst Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
2/27/2025 – Catalyst Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $33.00 price target on the stock.
2/4/2025 – Catalyst Pharmaceuticals is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $28.00 price target on the stock.
2/3/2025 – Catalyst Pharmaceuticals was upgraded by analysts at Baird R W to a “strong-buy” rating.
1/11/2025 – Catalyst Pharmaceuticals was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.

Catalyst Pharmaceuticals Stock Performance

CPRX traded up $0.14 during trading on Wednesday, reaching $21.10. The stock had a trading volume of 268,821 shares, compared to its average volume of 1,253,558. The business has a 50-day moving average of $22.27 and a 200-day moving average of $21.52. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64. The stock has a market cap of $2.56 billion, a PE ratio of 17.88, a PEG ratio of 3.31 and a beta of 0.84.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CPRX. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter worth $27,000. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $29,000. Farther Finance Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $65,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.